Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference

Audio By Carbonatix

SAN DIEGO--(BUSINESS WIRE)--Nov 24, 2025--

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Miami on Wednesday, December 3, 2025 at 1:20 p.m. ET.

An audio webcast of the fireside chat can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.

About Contineum Therapeutics

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and major depressive disorder. For more information, please visit www.contineum-tx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251124649214/en/

CONTACT: Steve Kunszabo

Contineum Therapeutics

Senior Director, Investor Relations & Corporate Communications

858-649-1158

[email protected]

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY MENTAL HEALTH HEALTH PHARMACEUTICAL CLINICAL TRIALS

SOURCE: Contineum Therapeutics

Copyright Business Wire 2025.

PUB: 11/24/2025 04:05 PM/DISC: 11/24/2025 04:05 PM

http://www.businesswire.com/news/home/20251124649214/en